Japan Lifeline Co., Ltd. Reports Consolidated Earnings Results for the Year Ended March 31, 2018; Provides earnings Guidance for the second quarter of Fiscal Year Ending March 31, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2019
May 01, 2018
Share
Japan Lifeline Co., Ltd. reported consolidated earnings results for the year ended March 31, 2018. For the year, the company has posted net sales of JPY 42,298 million against JPY 37,181 million a year ago. Operating income was JPY 10,671 million against JPY 7,685 million a year ago. Ordinary income was JPY 10,730 million against JPY 8,010 million a year ago. Net income was JPY 7,478 million against JPY 5,350 million a year ago. Diluted Earnings per share were JPY98.44. ROE was 24.2% against 29.2% a year ago. ROA was 21.2% against 20.9% a year ago. Cash flows from operating activities were JPY 4,450 million against JPY 6,584 million a year ago.
For the second quarter, the company expects net sales of JPY 22,902 million, operating income of JPY 4,617 million and Ordinary income of JPY 4,746 million, net income of JPY 3,217 million or JPY 40.01 per share.
For the full year ending March 31, 2019, the company expects net sales of JPY 49,411 million, operating income of JPY 11,202 million and Ordinary income of JPY 11,482 million, net income of JPY 7,825 million or JPY 97.32 per share.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.
Japan Lifeline Co., Ltd. Reports Consolidated Earnings Results for the Year Ended March 31, 2018; Provides earnings Guidance for the second quarter of Fiscal Year Ending March 31, 2019; Provides Earnings Guidance for the Full Year Ending March 31, 2019
JAPAN LIFELINE CO., LTD. 
